ID: ALA2349236

Max Phase: Preclinical

Molecular Formula: C28H42O5

Molecular Weight: 458.64

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCCCCCCCCCCCC(=O)C1=C(OCc2ccccc2)[C@@H](CO)OC1=O

Standard InChI:  InChI=1S/C28H42O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-17-20-24(30)26-27(25(21-29)33-28(26)31)32-22-23-18-15-14-16-19-23/h14-16,18-19,25,29H,2-13,17,20-22H2,1H3/t25-/m1/s1

Standard InChI Key:  AKJPJHLDVPBDRH-RUZDIDTESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 458.64

Molecular Weight (Monoisotopic): 458.3032

AlogP: 6.43

#Rotatable Bonds: 19

Polar Surface Area: 72.83

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.60

CX Basic pKa:

CX LogP: 7.47

CX LogD: 7.47

Aromatic Rings: 1

Heavy Atoms: 33

QED Weighted: 0.15

Np Likeness Score: 0.50

References

1. Gozalbes R, Mosulén S, Ortí L, Rodríguez-Díaz J, Carbajo RJ, Melnyk P, Pineda-Lucena A..  (2013)  Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches.,  21  (7): [PMID:23415087] [10.1016/j.bmc.2013.01.033]

2. Fu K, Bai Z, Chen L, Ye W, Wang M, Hu J, Liu C, Zhou W..  (2020)  Antitumor activity and structure-activity relationship of heparanase inhibitors: Recent advances.,  193  [PMID:32222663] [10.1016/j.ejmech.2020.112221]

3. Jia L, Ma S..  (2016)  Recent advances in the discovery of heparanase inhibitors as anti-cancer agents.,  121  [PMID:27240275] [10.1016/j.ejmech.2016.05.052]

Source

Source(1):

• Scientific Literature